Literature DB >> 19648879

Minor stroke as singular manifestation of hereditary thrombotic thrombocytopenic purpura in a young man.

A Lindblom1, S Thorsen, A Hillarp, P Björk.   

Abstract

The authors describe a case of a 38-year-old male with minor stroke due to exacerbation of hereditary deficiency of ADAMTS 13 resulting in a chronic relapsing form of thrombotic thrombocytopenic purpura (TTP). The clue to the unusual pathogenesis was given by laboratory findings of a mild anaemia and thrombocytopenia. After two days of observation, the patient was treated with plasmapheresis resulting in normalized platelet levels and continued clinical improvement. Subsequent clinical and laboratory investigation verified the diagnosis and the patient was put on regular treatments with plasma substitution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648879

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  4 in total

Review 1.  von Willebrand factor: an emerging target in stroke therapy.

Authors:  Simon F De Meyer; Guido Stoll; Denisa D Wagner; Christoph Kleinschnitz
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

2.  Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Wenjing Cao; Konstantine Halkidis; Mohammad S Abdelgawwad; Nicole K Kocher; Bryan Guillory; Lance A Williams; Radhika Gangaraju; Marisa B Marques; X Long Zheng
Journal:  Blood Adv       Date:  2019-12-23

3.  Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.

Authors:  Ruinan Lu; Jingrui Sui; X Long Zheng
Journal:  Blood Adv       Date:  2020-11-10

Review 4.  Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'.

Authors:  Peter Kraft; Simon F De Meyer; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2012-07-18       Impact factor: 6.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.